Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...
-
ICON releases its 2021 ESG report
ICON plc today (6 Sept, 2022) releases its 2021 Environmental, Social and Governance (ESG) Report.
-
ICON shareholders vote in favour of all resolutions at its annual general meeting
ICON plc today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 26, 2022 (which resolutions had all been recommended by the Board) were all duly passed by shareholders.
-
ICON reports second quarter 2022 results
Quarter 2 revenue of $1,935.2 million representing a year on year increase of 122.1%.
-
ICON establishes university scholarship programme to provide increased opportunities for underrepresented groups to study STEM-related courses
ICON establishes university scholarship programme to provide increased opportunities for underrepresented groups to study STEM-related courses.
-
ICON plc schedules second quarter 2022 earnings conference call
ICON plc schedules second quarter 2022 earnings conference call on Wednesday, July 27, 2022
-
ICON named Business & Finance Company of the Year and one of Forbes’ Best Employers for Diversity
ICON kick starts the first half of 2022 with a string of prestigious industry awards recognising healthcare intelligence work and staff, as independently judged by peers worldwide.
-
ICON reports first quarter 2022 results
Quarter 1 adjusted revenue of $1.901.8 million representing a year on year increase of 121.6% or 125% on a constant currency basis.
-
ICON reports fourth quarter and full year 2021 results
Record net business wins in the quarter of $2,378 million; a net book to bill of 1.26. Full year net business wins of $6,958 million; a net book to bill of 1.27.
-
ICON issues financial guidance for full year 2022
Full Year 2022 adjusted earnings per share guidance in the range of $11.55 - $11.95, representing growth of 21 – 23% over Full Year 2021 adjusted earnings per share guidance.
-
ICON named best contract research organisation in latest string of awards and recognitions
ICON and its drug and device development work continues to be recognised by peers, employees, and organisations around the globe.
